Beyond Air, Inc. Stock News

Related Stocks: XAIR ,

Beyond Air, Inc. (NASDAQ:XAIR) CEO Steven A. Lisi acquired 40,000 shares of the business’s stock in a transaction on Friday, December 10th. The stock was acquired at an average cost of $8.53 per share, with a total value of $341,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through […]

Goldman Sachs Group Inc. raised its position in Beyond Air, Inc. (NASDAQ:XAIR) by 134.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,586 shares of the companys stock after acquiring an additional 15,246 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.11% []

Beyond Air (NASDAQ:XAIR) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Analyst Recommendations This is a summary of recent recommendations for Beyond Air and Motus GI, []

Investors need to pay close attention to Beyond Air (XAIR) stock based on the movements in the options market lately.

Investors need to pay close attention to Beyond Air (XAIR) stock based on the movements in the options market lately.

The stock price of Beyond Air Inc (NASDAQ: XAIR) fell by over 30% this past week. This is why it happened.

A regulatory delay is weighing heavily on the medical device company's shares today.

GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR ), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced an update to the expectations for U.S. Food and Drug Administration (FDA) approval of LungFit ® PH for the treatment of persistent pulmonary hypertension of the newborn, or PPHN. Based upon our ongoing communications with the FDA, the Company no longer believes that the U.S. commercial launch of LungFit ® PH will take place prior to December 31, 2021. Beyond Air remains on track to receive CE Mark for LungFit ® PH in Europe in the first half of calendar year 2022. "The Beyond Air team continues to work towards our goal of bringing LungFit ® PH, the groundbreaking nitric oxide generator and delivery system, to NICUs across the United States and the world as soon as possible," commented Steve Lisi, Chairman and CEO of Beyond Air. "We commend the FDA for their continued commitment to provide us with a comprehensive review of our application.

Beyond Air Inc (NASDAQ: XAIR) expects a delay in FDA approval for LungFit PH for persistent pulmonary hypertension of the newborn. Based on ongoing communications with the FDA, the company no longe

Shares of Beyond Air, Inc. (NASDAQ:XAIR) have been given a consensus recommendation of Buy by the six analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have []

State Street Corp lessened its stake in shares of Beyond Air, Inc. (NASDAQ:XAIR) by 82.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 40,900 shares of the companys stock after selling 193,565 shares during the period. State Street Corps holdings in []

Beyond Air Inc. (NASDAQ:XAIR) price closed higher on Tuesday, December 07, jumping 4.63% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy